keyword
MENU ▼
Read by QxMD icon Read
search

bioresorbable vascular scaffold

keyword
https://www.readbyqxmd.com/read/29326152/decision-analytic-markov-model-weighting-expected-benefits-and-current-limitations-of-first-generation-bioresorbable-vascular-scaffolds-implications-for-manufacturers-and-next-device-iterations
#1
Davide Capodanno, Sergio Buccheri, Sara Romano, Piera Capranzano, Bruno Francaviglia, Corrado Tamburino
BACKGROUND: Relative benefits of bioresorbable vascular scaffolds (BVS) compared with everolimus-eluting stents (EES) are expected to accrue after complete bioresorption. METHODS AND RESULTS: We built a decision analytic Markov model comparing BVS and EES for a contemporary percutaneous coronary intervention population. Procedure-related morbidity and outcome data from the available literature were used to derive model probabilities. The net benefit of BVS and EES was estimated in terms of quality-adjusted life expectancy...
January 2018: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29322695/bioresorbable-scaffolds-in-coronary-intervention-unmet-needs-and-evolution
#2
REVIEW
Davide Capodanno
Bioresorbable scaffolds (BRS) represent a novel paradigm in the 40-year history of interventional cardiology. Restoration of cyclic pulsatility and physiologic vasomotion, adaptive vascular remodeling, plaque regression, and removal of the trigger for late adverse events are expected BRS benefits over current metallic drug-eluting stents. However, first-generation BRS devices have significant manufacturing limitations and rely on optimal implantation technique to avoid experiencing an excess of clinical events...
January 2018: Korean Circulation Journal
https://www.readbyqxmd.com/read/29321399/where-are-the-secrets-of-increased-thrombosis-and-aneurysm-formation-with-the-current-bioresorbable-vascular-scaffolds-hidden-%C3%A3-reply
#3
Jeehoon Kang, Hyo-Soo Kim
No abstract text is available yet for this article.
January 11, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/29321398/where-are-the-secrets-of-increased-thrombosis-and-aneurysm-formation-with-the-current-bioresorbable-vascular-scaffolds-hidden
#4
Nicholas G Kounis, Ioanna Koniari, Grigorios Tsigkas, George D Soufras, George Hahalis
No abstract text is available yet for this article.
January 11, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/29310720/direct-comparison-of-coronary-bare-metal-vs-drug-eluting-stents-same-platform-different-mechanics
#5
Wolfram Schmidt, Peter Lanzer, Peter Behrens, Christoph Brandt-Wunderlich, Alper Öner, Hüseyin Ince, Klaus-Peter Schmitz, Niels Grabow
BACKGROUND: Drug-eluting stents (DES) compared to bare metal stents (BMS) have shown superior clinical performance, but are considered less suitable in complex cases. Most studies do not distinguish between DES and BMS with respect to their mechanical performance. The objective was to obtain mechanical parameters for direct comparison of BMS and DES. METHODS: In vitro bench tests evaluated crimped stent profiles, crossability in stenosis models, elastic recoil, bending stiffness (crimped and expanded), and scaffolding properties...
January 8, 2018: European Journal of Medical Research
https://www.readbyqxmd.com/read/29281608/a-new-generation-of-drug-eluting-stents-indications-and-outcomes-of-bioresorbable-vascular-scaffolds
#6
REVIEW
Ron Waksman
Drug-eluting stents (DES) are increasingly being used as a less invasive alternative to coronary artery bypass grafting. Early generation DES had durable polymers that provided acceptable efficacy outcomes but had high rates of stent thrombosis leading to myocardial infarction and death. Second-generation DES have improved outcomes by reducing stent thrombosis and recurrent stenosis. Newer DES with biodegradable polymers have similar efficacy as second-generation DES, but have higher rates of stent thrombosis...
December 2017: Cleveland Clinic Journal of Medicine
https://www.readbyqxmd.com/read/29278353/long-term-safety-of-bioresorbable-scaffolds-insights-from-a-network-meta-analysis-including-91-trials
#7
Si-Hyuck Kang, Bill D Gogas, Ki-Hyun Jeon, Jie-Suck Park, Wonjae Lee, Chang-Hwan Yoon, Jung-Won Suh, Seung-Sik Hwang, Tae-Jin Youn, In-Ho Chae, Hyo-Soo Kim
AIMS: To investigate the long-term safety and efficacy of biodegradable scaffolds and metallic stents. METHODS AND RESULTS: We analyzed a total of 91 randomized controlled trials with a mean follow-up of 3.7 years in 105,842 patients which compared 2 or more coronary metallic stents or biodegradable scaffolds and reported the long-term clinical outcomes (≥2 years). Network meta-analysis showed that patients treated with the Absorb bioresorbable vascular scaffold (BVS) had significantly higher risk of definite or probable scaffold thrombosis (ScT) compared to those treated with metallic DES...
December 26, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29277145/long-term-intravascular-follow-up-of-coronary-bifurcation-treatment-with-absorb-bioresorbable-vascular-scaffold
#8
Maarten Vanhaverbeke, Keir McCutcheon, Christophe Dubois, Johan Bennett
No abstract text is available yet for this article.
December 25, 2017: Acta Cardiologica
https://www.readbyqxmd.com/read/29247976/coronary-calcification-as-a-mechanism-of-plaque-media-shrinkage-in-vessels-treated-with-bioresorbable-vascular-scaffold-a-multimodality-intracoronary-imaging-study
#9
Yaping Zeng, Rafael Cavalcante, Carlos Collet, Erhan Tenekecioglu, Yohei Sotomi, Yosuke Miyazaki, Yuki Katagiri, Taku Asano, Mohammad Abdelghani, Shaoping Nie, Christos V Bourantas, Nico Bruining, Yoshinobu Onuma, Patrick W Serruys
BACKGROUND AND AIMS: Whether coronary calcification is correlated with plaque/media shrinkage (PS) remains unclear. The aim of this study was to assess the relationship between the calcification process and PS, combining serial optical coherence tomography (OCT) and intravascular ultrasound (IVUS) in vessels treated with bioresorbable vascular scaffolds (BVS). METHODS: In 15 patients (16 vessels), OCT and IVUS images were matched using anatomic landmarks at post-procedure and five years...
December 2, 2017: Atherosclerosis
https://www.readbyqxmd.com/read/29247157/a-case-of-subacute-bioresorbable-vascular-scaffold-thrombosis-what-was-wrong
#10
Seraj A Abualnaja, Hanan M Alrammah, Bayan A Alsaif, Malak O Almulla, Bayan A Alzahrani
BACKGROUND The introduction of bioresorbable vascular scaffolds (BVS) into the field of percutaneous coronary intervention (PCI) was thought to be a promising step in solving the issues raised with the use of early bare metal stents (BMS) and drug eluting stents (DES); however, studies have raised concerns regarding thrombosis risk associated with the use of these stents. CASE REPORT A 42-year-old male presented with acute coronary syndrome (ACS), on diagnostic coronary angiography he had 75% and 70% stenosis in mid and distal left anterior descending artery (LAD) respectively, PCI with BVS implantation was done...
December 16, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29243353/first-in-human-evaluation-of-the-vascular-biocompatibility-and-biomechanical-performance-of-a-novel-ultra-high-molecular-weight-amorphous-plla-bioresorbable-scaffold-in-the-absence-of-anti-proliferative-drugs-two-year-imaging-results-in-humans
#11
Miguel Moncada, Juan A Delgado, Antonio Colombo, Pawel Gasior, Kamal Ramzipoor, Alex Estrada, Chang Lee, Danny Dokko, Juan F Granada
OBJECTIVES: In this first-in-human study, we prospectively studied the vascular compatibility and mechanical performance of a novel bare ultra-high molecular weight amorphous PLLA bioresorbable scaffold (BRS, FORTITUDE®, Amaranth Medical, Mountain View, California) up to two years after implantation using multimodality imaging techniques. BACKGROUND: The vascular biocompatibility of polymers used in BRS has not been fully characterized in the absence of anti-proliferative drugs...
December 15, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29235306/comparison-of-everolimus-eluting-bioresorbable-vascular-scaffolds-and-metallic-stents-three-year-clinical-outcomes-from-the-absorb-china-randomised-trial
#12
Bo Xu, Yuejin Yang, Yaling Han, Yong Huo, Lefeng Wang, Xiangqian Qi, Jifu Li, Yundai Chen, Hai-Chien Kuo, Shih-Wa Ying, Wai-Fung Cheong, Yunlong Zhang, Xiaolu Su, Jeffery Popma, Runlin Gao, Gregg Stone
Aims: Absorb bioresorbable vascular scaffolds (BVS) and XIENCE cobalt-chromium everolimus-eluting stents (CoCr-EES) had comparable angiographic and clinical outcomes up to one year in patients enrolled in the ABSORB China randomised trial. Whether these favourable results with BVS continue beyond one year up to three years is unknown. In this study we sought to analyse the outcomes from the trial up to three-year follow-up. Methods and results: ABSORB China was a prospective, open-label, multicentre trial in which 480 patients with one or two native coronary artery lesions were randomised 1:1 to BVS (N=241) vs...
October 22, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29223378/bioresorbable-vascular-scaffold-thrombosis-clinical-and-optical-coherence-tomography-findings
#13
Javier Cuesta, Marcos García-Guimaraes, Teresa Basante, Fernando Rivero, Paula Antuña, Fernando Alfonso
No abstract text is available yet for this article.
December 6, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/29217000/early-and-late-bioresorbable-vascular-scaffold-thrombosis-size-matters
#14
EDITORIAL
Manrique Alvarez, Robert J Applegate
No abstract text is available yet for this article.
December 11, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29216999/characteristics-predictors-and-mechanisms-of-thrombosis-in%C3%A2-coronary-bioresorbable-scaffolds-differences-between-early-and-late-events
#15
Tommaso Gori, Melissa Weissner, Svenja Gönner, Franziska Wendling, Helen Ullrich, Stephen Ellis, Remzi Anadol, Alberto Polimeni, Thomas Münzel
OBJECTIVES: The study sought to investigate the incidence, characteristics, predictors, and possible mechanisms of early and 3-year coronary scaffold thrombosis (ScT). BACKGROUND: An increased incidence of both early and late ScT has been shown in randomized trials. METHODS: Consecutive patients were enrolled in a single-center registry. Quantitative coronary angiography was performed. Incidence and predictors of ScT were assessed with Kaplan-Meier and Cox regression analyses...
December 11, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29216997/the-state-of-the-absorb-bioresorbable%C3%A2-scaffold-consensus-from-an-expert-panel
#16
REVIEW
Sripal Bangalore, Hiram G Bezerra, David G Rizik, Ehrin J Armstrong, Bruce Samuels, Srihari S Naidu, Cindy L Grines, Malcolm T Foster, James W Choi, Barry D Bertolet, Atman P Shah, Rebecca Torguson, Surendra B Avula, John C Wang, James P Zidar, Aziz Maksoud, Arun Kalyanasundaram, Steven J Yakubov, Bassem M Chehab, Anthony J Spaedy, Srini P Potluri, Ronald P Caputo, Ashok Kondur, Robert F Merritt, Amir Kaki, Ramon Quesada, Manish A Parikh, Catalin Toma, Fadi Matar, Joseph DeGregorio, William Nicholson, Wayne Batchelor, Raghava Gollapudi, Ethan Korngold, Riyaz Sumar, George S Chrysant, Jun Li, John B Gordon, Rajesh M Dave, Guilherme F Attizzani, Tom P Stys, Osvaldo S Gigliotti, Bruce E Murphy, Stephen G Ellis, Ron Waksman
Significant progress has been made in the percutaneous coronary intervention technique from the days of balloon angioplasty to modern-day metallic drug-eluting stents (DES). Although metallic stents solve a temporary problem of acute recoil following balloon angioplasty, they leave behind a permanent problem implicated in very late events (in addition to neoatherosclerosis). BRS were developed as a potential solution to this permanent problem, but the promise of these devices has been tempered by clinical trials showing increased risk of safety outcomes, both early and late...
December 11, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29191384/the-effect-of-bioresorbable-vascular-scaffold-implantation-on-distal-coronary-endothelial-function-in-dyslipidemic-swine-with-and-without-diabetes
#17
Mieke van den Heuvel, Oana Sorop, Nienke S van Ditzhuijzen, René de Vries, Richard W B van Duin, Ilona Krabbendam-Peters, Janine E van Loon, Moniek P de Maat, Heleen M van Beusekom, Wim J van der Giessen, A H Jan Danser, Dirk J Duncker
BACKGROUND: We studied the effect of bioresorbable vascular scaffold (BVS) implantation on distal coronary endothelial function, in swine on a high fat diet without (HFD) or with diabetes (DM+HFD). METHODS: Five DM+HFD and five HFD swine underwent BVS implantation on top of coronary plaques, and were studied six months later. Conduit artery segments >5mm proximal and distal to the scaffold and corresponding control segments of non-scaffolded coronary arteries, as well as segments of small arteries within the flow-territories of scaffolded and non-scaffolded arteries were harvested for in vitro vasoreactivity studies...
November 20, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29171715/restenosis-patterns-after-bioresorbable-vascular-scaffold-implantation-angiographic-substudy-of-the-ghost-eu-registry
#18
Moritz Baquet, Holger Nef, Tomasso Gori, Azeem Latib, Davide Capodanno, Carlo Di Mario, Manel Sabate, Antonio Colombo, Corrado Tamburino, Julinda Mehilli
OBJECTIVES: To evaluate pattern of in-BVS-restenosis after bioresorbable vascular scaffold (BVS) implantation. BACKGROUND: In-stent restenosis morphology impacts target lesion revascularization (TLR) rates and clinical outcomes. Although several trials report on outcomes after BVS implantation, information about in-BVS restenosis pattern is still lacking. METHODS: Between November 2011 and January 2014, in 7 of 10 European centers participating in the GHOST-EU registry, 668 patients underwent BVS implantation...
November 24, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29171214/bioresorbable-vascular-scaffold-korean-expert-panel-report
#19
REVIEW
Jung Min Ahn, Duk Woo Park, Sung Jin Hong, Young Keun Ahn, Joo Yong Hahn, Won Jang Kim, Soon Jun Hong, Chang Wook Nam, Do Yoon Kang, Seung Yul Lee, Woo Jung Chun, Jung Ho Heo, Deok Kyu Cho, Jin Won Kim, Sung Ho Her, Sang Wook Kim, Sang Yong Yoo, Myeong Ki Hong, Seung Jea Tahk, Kee Sik Kim, Moo Hyun Kim, Yangsoo Jang, Seung Jung Park
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea...
November 6, 2017: Korean Circulation Journal
https://www.readbyqxmd.com/read/29168541/evaluation-of-bioresorbable-vascular-scaffolds-in-acute-coronary-syndrome-a-two-center-one-year-follow-up-analysis
#20
Sylwia Iwańczyk, Jarosław Hiczkiewicz, Aleksander Araszkiewicz, Magdalena Łanocha, Daria Adamczak, Wojciech Faron, Stefan Grajek, Maciej Lesiak
BACKGROUND: Bioresorbable vascular scaffolds (BVS) have emerged as a new treatment option in cardiovascular medicine. Nonetheless, there is still limited data on the use of these novel devices in patients with acute coronary syndromes (ACS). The purpose of this study was to evaluate the feasibility and efficacy of BVS implantation in patients with ACS. METHODS: The present report is a prospective, two-centre registry that involved 165 consecutive patients hospitalized with the diagnosis of ACS and treated with the Absorb BVS (Abbot Vascular, Santa Clara, USA)...
November 23, 2017: Cardiology Journal
keyword
keyword
74350
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"